scholarly journals Bilateral Optic Disc Swelling as a Plausible Common Ocular Sign of Autoinflammatory Diseases: Report of Three Patients with Blau Syndrome or Cryopyrin-Associated Periodic Syndrome

Life ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 1433
Author(s):  
Toshihiko Matsuo ◽  
Masato Yashiro ◽  
Osamu Yamasaki ◽  
Takehiro Tanaka ◽  
Akira Manki

The aim of this study is to describe bilateral optic disc swelling in three consecutive patients with Blau syndrome or cryopyrin-associated periodic syndrome at a single institution. Case 1 was a 30-year-old woman receiving 25 mg etanercept twice weekly who had been diagnosed as early-onset sarcoidosis by biopsy of skin rashes at 5 months old and genetically diagnosed with Blau syndrome with CARD15/NOD2 mutation (N670K) at 13 years old. At 10 years old, she began to have uveitis with optic disc swelling in both eyes, resulting in macular degeneration and optic disc atrophy at 17 years old only when etanercept was introduced. Case 2 was a 21-year-old man receiving adalimumab every 2 weeks who had been diagnosed as early-onset sarcoidosis by biopsy of skin rashes at 1.5 years old and genetically diagnosed as Blau syndrome with CARD15/NOD2 mutation (C495Y) at 5 years old. At 8 years old, around the time of adalimumab introduction, he began to show bilateral optic disc swelling which continued until the age of 16 years when the dose of adalimumab was increased. Case 3 was a 20-year-old woman receiving canakinumab every 8 weeks for systemic symptoms such as fever, headache, vomiting, and abdominal pain and later for sensorineural hearing disturbance on both sides. She had been diagnosed genetically with cryopyrin-associated periodic syndrome with NLRP3 mutation (Y859C) at 7 years old. At 5 years old, she was found to have bilateral optic disc swelling, which continued until the age of 10 years when she began receiving canakinumab (IL-1β inhibitor). Bilateral optic disc swelling might be tentatively designated as a plausible common ocular feature, if it occurred, in autoinflammatory diseases to pay more attention to ophthalmic complications in rare diseases.

2017 ◽  
Vol 23 (7) ◽  
pp. 578-583 ◽  
Author(s):  
Lawrence TC Ong ◽  
Ueli Nachbur ◽  
Dorota Rowczenio ◽  
John B Ziegler ◽  
Eddy Fischer ◽  
...  

Mutations in the nucleotide binding domain of the PRR, NOD2, are associated with the autoinflammatory diseases Blau syndrome and early-onset sarcoidosis. Current theories suggest that constitutive activation of the NOD2 pathway may be responsible for pathogenesis of these diseases. Here, we report the phenotype of a kindred with Blau syndrome caused by a novel NOD2 mutation (p.E383D). Signaling protein and cytokine expression were examined, and the results of these experiments challenge current theories of constitutive NOD2 activation in the pathophysiology of Blau syndrome.


2013 ◽  
Vol 23 (4) ◽  
pp. 837-839 ◽  
Author(s):  
Yuzaburo Inoue ◽  
Yasushi Kawaguchi ◽  
Naoki Shimojo ◽  
Kenichi Yamaguchi ◽  
Yoshinori Morita ◽  
...  

2007 ◽  
Vol 157 (6) ◽  
pp. 1257-1259 ◽  
Author(s):  
P. Coto-Segura ◽  
S. Mallo-Garcia ◽  
M. Costa-Romero ◽  
J.I. Arostegui ◽  
J. Yague ◽  
...  

2020 ◽  
Vol 18 ◽  
pp. 100714
Author(s):  
María Alejandra Marín-Noriega ◽  
Juliana Muñoz-Ortiz ◽  
Catalina Mosquera ◽  
Alejandra de-la-Torre

Rheumatology ◽  
2020 ◽  
Vol 59 (5) ◽  
pp. 1190-1190
Author(s):  
Jessica C Ellis ◽  
Benjamin G Faber ◽  
Ishaq F Uri ◽  
Sarah J Emerson

RMD Open ◽  
2015 ◽  
Vol 1 (1) ◽  
pp. e000097 ◽  
Author(s):  
Francesco Caso ◽  
Paola Galozzi ◽  
Luisa Costa ◽  
Paolo Sfriso ◽  
Luca Cantarini ◽  
...  

2010 ◽  
Vol 62 (1) ◽  
pp. 250-257 ◽  
Author(s):  
Kozo Yasui ◽  
Masato Yashiro ◽  
Mitsuru Tsuge ◽  
Akira Manki ◽  
Kei Takemoto ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Tomoyuki Iwasaki ◽  
Naoe Kaneko ◽  
Yuki Ito ◽  
Hiroyuki Takeda ◽  
Tatsuya Sawasaki ◽  
...  

Nucleotide-binding oligomerization domain-containing protein (Nod) 2 is an intracellular pattern recognition receptor, which recognizes muramyl dipeptide (N-Acetylmuramyl-L-Alanyl-D-Isoglutamine: MDP), a bacterial peptidoglycan component, and makes a NF-κB-activating complex called nodosome with adaptor protein RICK (RIP2/RIPK2). Nod2 mutants are associated with the autoinflammatory diseases, Blau syndrome (BS)/early-onset sarcoidosis (EOS). For drug discovery of BS/EOS, we tried to develop Nod2-nodosome in a cell-free system. FLAG-tagged RICK, biotinylated-Nod2, and BS/EOS-associated Nod2 mutants were synthesized, and proximity signals between FLAG-tagged and biotinylated proteins were detected by amplified luminescent proximity homogeneous assay (ALPHA). Upon incubation with MDP, the ALPHA signal of interaction between Nod2-WT and RICK was increased in a dose-dependent manner. The ALPHA signal of interaction between RICK and the BS/EOS-associated Nod2 mutants was more significantly increased than Nod2-WT. Notably, the ALPHA signal between Nod2-WT and RICK was increased upon incubation with MDP, but not when incubated with the same concentrations, L-alanine, D-isoglutamic acid, or the MDP-D-isoform. Thus, we successfully developed Nod2-nodosome in a cell-free system reflecting its function in vivo, and it can be useful for screening Nod2-nodosome-targeted therapeutic molecules for BS/EOS and granulomatous inflammatory diseases.


Rheumatology ◽  
2019 ◽  
Vol 59 (5) ◽  
pp. 1179-1180
Author(s):  
Jessica C Ellis ◽  
Benjamin G Faber ◽  
Ishaq F Uri ◽  
Sarah J. Emerson

Sign in / Sign up

Export Citation Format

Share Document